News

The radiopharmaceutical industry is growing very quickly. In the past few years, there have been more mergers and acquisitions (M&A) and partnerships. Investors can find good business chances by learning more about this field. Recent mergers, purchases, and joint deals...

The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion agreement last year. The pharma firm said that GSK5764227 (GSK'227, formerly known as HS-20093) has been granted the...

Bayer and NextRNA Therapeutics, a biotechnology company, announced that they would be working together to create a new type of small molecule cancer drug. The two companies agreed to a deal that could be worth over $500 million. The two...

The capacity of a cell line to create a biologic that is both safe and stable in large numbers may be considerably improved by the use of a variety of procedures by those who develop pharmaceuticals. On the other...

The North American nuclear medicine market was estimated to be worth USD 2.05 billion in 2023 and is expected to develop rapidly over the next few years, with a compound annual growth rate (CAGR) of 9.90% through 2029. Within the...

This summer, Bayer officials made sure Fierce understood that the company's desire for deals hasn't been stifled by a group-wide reorganization. Its most recent partnership aimed at treating cancer indicates that Bayer has, in fact, not lost interest in...

The most recent trial of a new antibody drug that goes on to deliver potent chemotherapy that too directly to the cancer cells for patients with advanced or recurrent endometrial cancer has gone a notch up to be studied...